Emergent BioSolutions | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 126.37M 3.71M 2025-03
ALKERMES USD 171.7M 24.71M 2025-03
Alnylam Pharmaceuticals USD 239.95M 55.39M 2025-03
Amarin USD 36.57M 397K 2025-03
ANI Pharmaceuticals USD 76.53M 6.81M 2025-03
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Exact Sciences USD 485M 114.56M 2025-03
Exelixis USD 137.18M 2.86M 2025-04
Glaxosmithkline GBP 2.7B 632M 2024-12
Ionis Pharmaceuticals USD 76M 12.08M 2025-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Merck USD 2.53B 319M 2025-03
Moderna USD 212M 139M 2025-03
Myriad Genetics USD 135.7M 300K 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Pacira USD 86.78M 7.16M 2025-03
Pfizer USD 3.01B 1.27B 2025-03
PTC Therapeutics USD 161.92M 77.24M 2025-03
Sanofi EUR 2.22B 980M 2025-03
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
United Therapeutics USD 170.1M 7.6M 2025-03



Emergent BioSolutions Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Jul 2025.